TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12900682

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3; 0.3 g.kg−1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl; 0.045 g.kg−1)
Number of subjects: 8
Study: 11011709

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral PRK
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sequential bilateral PRK
Number of subjects: 52
Study: 9348450

Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 32 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 59 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: RGP scleral lenses with Dk 115 and thicknesses of 0.15, 0.30, 0.60, and 1.20 mm
Number of subjects: 4
Study: 8450243

Group type: EXPERIMENTAL
Intervention: Nucleoside therapy (zidovudine, 2',3'-dideoxyinosine, or both) for a mean of 20 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nucleoside therapy
Number of subjects: 36
Study: 3739801

Group type: EXPERIMENTAL
Intervention: Calorie-counting diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exchange system diet
Number of subjects: 0
Study: 30261350

Group type: EXPERIMENTAL
Intervention: Elaborative reminiscing intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 88
Study: 27113376

Group type: EXPERIMENTAL
Intervention: Intervention group (prenatal and postpartum individual nutrition/breastfeeding counseling)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 533
Study: 24805282

Group type: EXPERIMENTAL
Intervention: SONO (ultrasound-guided quadruple injection axillary block)
Number of subjects: 60

Group type: COMPARATOR
Intervention: STIM (nerve stimulation-guided triple injection axillary block)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SONO
Number of subjects: 60

Group type: COMPARATOR
Intervention: STIM
Number of subjects: 60
Study: 23186567

Group type: EXPERIMENTAL
Intervention: 7.5% povidone iodine mouthrinse
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.9% NaCl (sterile saline) solution
Number of subjects: 34
Study: 20473257

Group type: COMPARATOR
Intervention: High-dose corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-dose corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-duration, high-dose glucocorticoid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses for persistent ARDS
Number of subjects: 0
Study: 17703218

Group type: EXPERIMENTAL
Intervention: Prelox (combination of L‐arginine aspartate and Pycnogenol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15877558

Group type: EXPERIMENTAL
Intervention: Capsaicin troche supplementation before every meal for 4 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Capsaicin troche supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo troche
Number of subjects: 64
Study: 12422064

Group type: EXPERIMENTAL
Intervention: 50 mg opipramol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100 mg opipramol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 10325662

Group type: EXPERIMENTAL
Intervention: Active NSAID (Piroxicam 20 mg)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Active NSAID (Meloxicam 15 mg)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Active NSAID (Meloxicam 22.5 mg)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Meloxicam 22.5 mg
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 473
Study: 8952580

Group type: EXPERIMENTAL
Intervention: Apneic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonapneic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both apneic and nonapneic subjects during stages 3 and 4 of non-REM sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apneic subjects with ischemic heart disease
Number of subjects: 0
Study: 1770156

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 1, 6, and 12 nights
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 12 nights
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 12 nights
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg for 1 and 6 nights
Number of subjects: 11
Study: 7196801

Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, and 5-FU (AVF)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, and 5-FU (AVF) after failing CTX
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) after failing AVF
Number of subjects: 61
Study: 30329163

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid nanoemulsion (BF-200 ALA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: methyl-5-aminolaevulinate (MAL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: methyl-5-aminolaevinate (MAL)
Number of subjects: 69
Study: 29914494

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise and behavioural support intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 350
Study: 27964756

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2 g
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Combination of RF, anti-CCP, and high serum IgG
Number of subjects: 185
Study: 24682844

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 21761707

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Focused ultrasound
Number of subjects: 86
Study: 20025635

Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones (60 mg of genistein)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 18162021

Group type: EXPERIMENTAL
Intervention: Aripiprazole (20-30 mg/day)
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Haloperidol (5-10 mg/day)
Number of subjects: 1294
Study: 15238035

Group type: EXPERIMENTAL
Intervention: Prototype model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemplar model with response-scaling mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype model and exemplar model with response-scaling mechanism
Number of subjects: 0
Study: 11546945

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 120 mg once daily
Number of subjects: 505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study: 9128034

Group type: EXPERIMENTAL
Intervention: Low flow anesthesia (300 ml.min‐1 of oxygen, 300 ml.min‐1 of nitrous oxide or 400 ml.min‐1 of oxygen, 200 ml.min‐1 of nitrous oxide)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High flow anesthesia (2 l.min‐1 of oxygen, 4 l.min‐1 of nitrous oxide)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: High flow anesthesia
Number of subjects: 39
Study: 8179457

Group type: EXPERIMENTAL
Intervention: Heparin protocol (5000 U bolus, followed by 1680 U/h or 1240 U/h)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-protocol physician management
Number of subjects: 68
Study: 3067749

Group type: EXPERIMENTAL
Intervention: Daily relaxation technique for 3 weeks
Number of subjects: 24
Study: 31550904

Group type: EXPERIMENTAL
Intervention: ACT‐Open (acceptance, defusion components)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ACT‐Engaged (values, committed action)
Number of subjects: 55

Group type: COMPARATOR
Intervention: ACT‐Combined (acceptance, defusion, values, committed action)
Number of subjects: 55
Study: 30356245

Group type: EXPERIMENTAL
Intervention: School corporal punishment
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Home corporal punishment
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Peer violence
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: School performance and attendance
Number of subjects: 1752
Study: 27554636

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24857397

Group type: EXPERIMENTAL
Intervention: Levothyroxine supplementation (1‐3μg/kg/day) for 120 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo for 120 days
Number of subjects: 28
Study: 22348983

Group type: EXPERIMENTAL
Intervention: lasofoxifene 0.5mg/d
Number of subjects: 1126

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1126
Study: 20008155

Group type: EXPERIMENTAL
Intervention: Two antismoking ads
Number of subjects: 84

Group type: COMPARATOR
Intervention: Two prosocial ads
Number of subjects: 84

Group type: COMPARATOR
Intervention: Smoking portrayal in the movie
Number of subjects: 84

Group type: COMPARATOR
Intervention: No smoking portrayal in the movie
Number of subjects: 84
Study: 18724648

Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04% applied once nightly for 12 weeks
Number of subjects: 629

Group type: COMPARATOR
Intervention: Vehicle gel (placebo)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04%
Number of subjects: 629
Study: 16215369

Group type: COMPARATOR
Intervention: Standard care (placebo arms of two trials)
Number of subjects: 1036
Study: 12929008

Group type: EXPERIMENTAL
Intervention: Harvesting from the ventral iliac crest
Number of subjects: 113

Group type: COMPARATOR
Intervention: Harvesting from the dorsal iliac crest
Number of subjects: 113
Study: 10563706

Group type: EXPERIMENTAL
Intervention: Concurrent therapy with zidovudine, lamivudine, loviride and zalcitabine (T4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclical therapy with the same four drugs (C4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Concurrent zidovudine and lamivudine (T2)
Number of subjects: 100
Study: 8688345

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg suppository once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ondansetron 8 mg tablets twice daily
Number of subjects: 20
Study: 1677822

Group type: EXPERIMENTAL
Intervention: Atracurium (group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Metocurine plus pancuronium (group MP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vecuronium (group V)
Number of subjects: 64
Study: 6217921

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: aspirin/dipyridamole
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 30007039

Group type: EXPERIMENTAL
Intervention: PRF alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PRF + 1% Alendronate (ALN) gel
Number of subjects: 40
Study: 30201456

Group type: EXPERIMENTAL
Intervention: Upper limb ischemic postconditioning (LIPostC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 60
Study: 26787231

Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR) defined as >3.0
Number of subjects: 908

Group type: COMPARATOR
Intervention: Low neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 908
Study: 25169796

Group type: EXPERIMENTAL
Intervention: Normal PR interval group (n=199)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Prolonged PR interval group (n=204)
Number of subjects: 403
Study: 22166897

Group type: EXPERIMENTAL
Intervention: Rose hip powder drink
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 31
Study: 19384775

Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 33
Study: 17931465

Group type: EXPERIMENTAL
Intervention: Invariant paradigm with pairs of 2-digit numbers governed by a rule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invariant paradigm with controlled biases in Experiments 2 and 3
Number of subjects: 0
Study: 15015149

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11432031

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for orthopaedic surgery
Number of subjects: 0
Study: 9645977

Group type: EXPERIMENTAL
Intervention: Best medical care plus carotid endarterectomy (CE)
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1996
Study: 7916914

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl)
Number of subjects: 0
Study: 2811648

Group type: EXPERIMENTAL
Intervention: Single drug for movement disorder
Number of subjects: 2

Group type: COMPARATOR
Intervention: Potentially useful but toxic drug
Number of subjects: 2
Study: 1244405

Group type: EXPERIMENTAL
Intervention: Physical-mental practice
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: One-half physical practice
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 140
Study: 29208758

Group type: EXPERIMENTAL
Intervention: Impedance-based respiratory volume monitor (RVM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 26597211

Group type: EXPERIMENTAL
Intervention: Statin use (475 patients, 43.5% of the population)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Control group (non-statin users)
Number of subjects: 1093
Study: 25068456

Group type: EXPERIMENTAL
Intervention: Weight stigma exposure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Perceived stress mediation
Number of subjects: 45
Study: 22409880

Group type: EXPERIMENTAL
Intervention: GW274150 60 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20858230

Group type: EXPERIMENTAL
Intervention: Training on infectious diseases (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of rapid diagnostic tests (RDTs) (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of training and RDTs (AB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study: 19039291

Group type: EXPERIMENTAL
Intervention: Home-based video exercise program (26 minutes, three times per week for five months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (bi-weekly telephone call, no exercise intervention)
Number of subjects: 61
Study: 17575754

Group type: EXPERIMENTAL
Intervention: Right paracolic adhesiolysis
Number of subjects: 25

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy (for all subjects)
Number of subjects: 25
Study: 14666757

Group type: EXPERIMENTAL
Intervention: TCM treatment based on syndrome differentiation of TCM
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional method of western medicine (Control)
Number of subjects: 82
Study: 11011339

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Subtherapeutic
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Therapeutic
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) - Supratherapeutic
Number of subjects: 3831
Study: 8865767

Group type: EXPERIMENTAL
Intervention: Online tutorial group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Text guide group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pictorial guide group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Description group
Number of subjects: 56
Study: 1818759

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU) daily injections
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 56
Study: 6827742

Group type: EXPERIMENTAL
Intervention: Computer data base
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Literature summary and patient registry features
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Randomized control trials (RCTs)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Randomized control trials (RCTs) and patient registries
Number of subjects: 1016
Study: 31137756

Group type: EXPERIMENTAL
Intervention: Typical warm-up (WU)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Warm-up complemented with ballistic exercises (PAP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 11
Study: 30136069

Group type: EXPERIMENTAL
Intervention: Peer Mentors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 26455450

Group type: EXPERIMENTAL
Intervention: XEN-D0103 (3 µM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: XEN-D0103 (10 µM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: XEN-D0103
Number of subjects: 3
Study: 24501044

Group type: EXPERIMENTAL
Intervention: Activation of mating motives
Number of subjects: 0
Study: 22371887

Group type: EXPERIMENTAL
Intervention: Rituximab plus ABVD (RABVD)
Number of subjects: 85
Study: 20350025

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 244
Study: 17537289

Group type: EXPERIMENTAL
Intervention: Cobalamin (1000 microg) plus Folic Acid (400 microg)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cobalamin (1000 microg)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cobalamin plus Folic Acid
Number of subjects: 195
Study: 16286135

Group type: EXPERIMENTAL
Intervention: Benique sound‐Karl Storz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional sound
Number of subjects: 0
Study: 11897434

Group type: EXPERIMENTAL
Intervention: Low serum digoxin concentration (0.5 to 0.9 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate serum digoxin concentration (0.9 to 1.2 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High serum digoxin concentration (>1.2 ng/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (digoxin withdrawn)
Number of subjects: 0
Study: 10194736

Group type: EXPERIMENTAL
Intervention: Light‐cone technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Incremental layering technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Curing light transmission into the proximal box
Number of subjects: 20
Study: 7762545

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bromocriptine and Placebo
Number of subjects: 29
Study: 2271507

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (Ara‐A) 15 mg/Kg, iv, for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha‐interferon (alpha‐INF) 3 million units, sc, every other day for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha‐interferon (alpha‐INF)
Number of subjects: 40
Study: 10248153

Group type: EXPERIMENTAL
Intervention: Specific teaching of interviewing techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 31390002

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) at 1000 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28866974

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 8800

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8800
Study: 26240949

Group type: EXPERIMENTAL
Intervention: Outpatient polypectomy
Number of subjects: 507

Group type: COMPARATOR
Intervention: Inpatient polypectomy
Number of subjects: 507

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 507
Study: 23984840

Group type: EXPERIMENTAL
Intervention: SCOPE questionnaire alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SCOPE questionnaire with a complementary workshop
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control arm (care as usual)
Number of subjects: 30
Study: 21140163

Group type: EXPERIMENTAL
Intervention: Frontal plane proprioception (varus/valgus)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sagittal plane proprioception (flexion/extension)
Number of subjects: 17
Study: 19786219

Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 60
Study: 16769988

Group type: EXPERIMENTAL
Intervention: EC + G‐CSF
Number of subjects: 506

Group type: COMPARATOR
Intervention: EC alone
Number of subjects: 506

Group type: COMPARATOR
Intervention: Schedule 5 G‐CSF
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Seven or four G‐CSF injections
Number of subjects: 506
Study: 15497904

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Superficial needle insertion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 45
Study: 11672897

Group type: EXPERIMENTAL
Intervention: RIVM hexavalent OMV vaccine (three doses at 0, 2, and 8 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RIVM hexavalent OMV vaccine
Number of subjects: 0